FRAX1036 - PAK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEFRAX1036Cat. No.: HY-19538CAS No.: 1432908-05-8分式: CHClNO分量: 518.05作靶點: PAK作通路: Cell Cycle/DNA Damage; Cytoskeleton儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 5.3 mg/mL (10.23 mM; Need

2、warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.9303 mL 9.6516 mL 19.3032 mL5 mM 0.3861 mL 1.9303 mL 3.8606 mL10 mM 0.1930 mL 0.9652 mL 1.9303 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 FRAX1036種 PAK 抑制劑，對 PAK1，PAK2 和 PAK4 的 Ki 值分別為 23.3 nM，72.4 nM 和 2.4 M。IC50

3、 & Target PAK1 PAK2 PAK423.3 nM (Ki) 72.4 nM (Ki) 2.4 M (Ki)體外研究FRAX1036 is a PAK inhibitor with Kis of 23.3 nM, 72.4 nM, and 2.4 M for PAK1, PAK2 and PAK4,respectively. FRAX1036 (2.5 M) incombination with docetaxel alters stathmin phosphorylation, induces the1/3 Master of Small Molecules 您邊的抑制劑師www

4、.MedChemEapoptotic marker cleaved PARP and increases kinetics of apoptosis in MDA-MB-175 and HCC2911 cells;also alters microtubule organization, mitosis and cell fate in U2OS cells. Moreover, FRAX1036 showssignificantly effective inhibition on U2OS cells 1. FRAX1036 (10 M) affects the proliferation

5、of non-smallcell lung cancer (NSCLC) cells when added to KRAS prenylation inhibitors 2.PROTOCOLKinase Assay 1 The activity/inhibition of human recombinant PAK1 (kinase domain), PAK2 (full length) or PAK4 (kinasedomain) is estimated by measuring the phosphorylation of a FRET peptide substrate (Ser/Th

6、r19) labeled withCoumarin and Fluorescein using Z-LYTETM assay. The 10 L assay mixtures containe 50 mM HEPES (pH7.5), 0.01% Brij-35, 10 mM MgCl2, 1 mM EGTA, 2 M FRET peptide substrate, and PAK enzyme (20 pMPAK1; 50 pM PAK2; 90 pM PAK4). Incubations are carried out at 22C in black polypropylene 384-w

7、ellplates. Prior to the assay, enzyme, FRET peptide substrate and serially diluted test compounds (FRAX1036,etc.) are preincubated together in assay buffer (7.5 L) for 10 minutes, and the assay is initiated by theaddition of 2.5 L assay buffer containing 4 ATP (160 M PAK1; 480 M PAK2; 16 M PAK4). Fo

8、llowingthe 60-minute incubation, the assay mixtures are quenched by the addition of 5 L of Z-LYTETMdevelopment reagent, and 1 hour later the emissions of Coumarin (445 nm) and Fluorescein (520 nm) aredetermined after excitation at 400 nm. An emission ratio (445 nm/520 nm) is determined to quantify t

9、hedegree of substrate phosphorylation 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 For caspase 3/7 activation apoptosis assays, cells are plated at 10,000 cells/well in 96-well plates for 24hours prior to treating with DMSO, FRAX1036,

10、and/or docetaxel. Caspase 3/7 reagent is added at a 1:1000dilution. Cells are imaged at 10 magnification in an IncuCyte Zoom Live-content imaging system at 37C,5% CO2. Images are acquired every 2 hours or 4 hours for 36 to 72 hours, two images/well. Data is analyzedusing IncuCyte analysis software t

11、o detect and quantify green (apoptotic) cells/image. Each condition isperformed in triplicate. Averages with SEM at each time point are plotted in Excel. A t-test is performed forthe final time point comparing the combination of FRAX1036 and docetaxel with each single agent in Prism.The apoptotic in

12、dex is calculated from the apoptosis assays by dividing the final apoptotic cell count by thetotal cell count. Averages with SEM are plotted in Excel, and a t-test is performed comparing the combinationof FRAX1036 and docetaxel with each single agent in Prism 1.MCE has not independently confirmed th

13、e accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Elife. 2017 Mar 13;6. pii: e22207.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Ong CC, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEof microtubule stabilizing agents. Breast Cancer Res. 2015 Apr 23;17:59.2. Mortazavi F, et al. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC Cancer. 2015 May9;1